一种抗体-寡核酸结合物用于1型肌性发育不良
Nicholas E Johnson1, Li-Jung Tai2, Johanna I Hamel3
1Virginia Commonwealth University, Richmond.
The New England journal of medicine
|February 18, 2026
概括
德尔帕西巴特 (del-desiran) 在治疗1型肌性缩症方面表现有前途,通过减少有毒的mRNA和改善拼接模式. 尽管观察到一些严重的不良事件,但需要进一步进行临床研究.
科学领域:
- 神经肌肉疾病 神经肌肉疾病
- 在RNA治疗方面,RNA疗法.
- 遗传医学是一种遗传医学.
背景情况:
- 肌性缩症1型 (DM1) 是一种进展性,遗传性神经肌肉疾病,目前没有治疗方法.
- DM1的结果是DMPKmRNA中的三核酸重复扩张,导致功能有毒增长和替代拼接缺陷.
- 德尔帕西巴特 (delpacibart etedesiran,del-desiran) 是一种针对DMPK mRNA的试验性疗法.
研究的目的:
- 评估delpacibart etedesiran在DM1患者中的安全性,药理动力学和药理动力学.
- 评估del-desiran对DM1中异常的替代拼接模式的影响.
主要方法:
- 进行了一阶段1-2,多中心,双盲,随机,安慰剂对照试验.
- 参与者接受了单次或多次静脉注射剂量的del-desiran (1-4 mg/kg) 或安慰剂.
- 评估了安全性,药理动力学/药理动力学概况以及拼接分数的变化.
主要成果:
- 德尔德西兰治疗导致肌肉活检中的DMPKmRNA水平显著降低.
- 观察到错误分数的减少,特别是在2毫克和4毫克组.
- 轻度至中度的不良事件很常见;报告有两起严重的不良事件.
结论:
- 德尔-德西兰证明了DM1患者的肌肉输送和异常拼接的改善.
- 观察到的安全性和有效性支持进一步对del-desiran进行临床研究.
- 发现了两种严重的不良事件,需要在未来的试验中仔细监测.
相关概念视频
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
1.2K
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
1.2K
Satellite Stem Cells and Muscular Dystrophy
2.4K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.4K
Myasthenia Gravis: Overview and Treatment
3.1K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.1K
Antibody Structure
65.9K
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
65.9K
Myasthenia Gravis: Diagnostic Tests
2.8K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
2.8K
Hybridoma Technology
17.9K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
17.9K


